@article{d383203f97bf4743b2260bc3087ebf22,
title = "Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction*",
keywords = "Diastolic dysfunction, Heart failure with preserved ejection fraction, Late sodium current inhibition",
author = "Mihai Gheorghiade and Muthiah Vaduganathan and Shah, {Sanjiv J.}",
note = "Funding Information: Dr. Gheorghiade has received research support or consultation fees from Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd, CorThera, Cytokinetics, CytoPherx, Inc., DebioPharm S.A., Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Intersection Medical, Inc., Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Parmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, sanofi-aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America, Inc., and Trevena Therapeutics; and has received significant (>$10,000) support from Bayer Schering Pharma AG, DebioPharm S.A., Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, and Takeda Pharmaceuticals North America, Inc. Dr. Shah has received grants from the National Institutes of Health , American Heart Association , and Gilead Sciences; and has served on an advisory board for Bristol-Myers Squibb . Dr. Vaduganathan has reported that he has no relationships relevant to the contents of this paper to disclose. ",
year = "2013",
month = apr,
doi = "10.1016/j.jchf.2013.01.001",
language = "English (US)",
volume = "1",
pages = "123--126",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "2",
}